{"id":"insulin-degludec-liraglutide-injectable-product","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"10-20","effect":"Diarrhea"},{"rate":"variable","effect":"Hypoglycemia"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin degludec is an ultra-long-acting basal insulin analog that provides steady glucose control over 24+ hours. Liraglutide is a GLP-1 receptor agonist that stimulates insulin secretion in response to meals, slows gastric emptying, and promotes satiety. Together, they address both fasting and postprandial glucose levels while supporting weight loss.","oneSentence":"This combination product uses insulin degludec to provide long-acting basal insulin coverage and liraglutide to stimulate GLP-1 receptors, enhancing insulin secretion and reducing appetite for improved glycemic control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:13.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06449703","phase":"PHASE1","title":"A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects","status":"RECRUITING","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2024-05-06","conditions":"Healthy","enrollment":44},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03862716","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Insulin Degludec/Liraglutide"],"phase":"marketed","status":"active","brandName":"Insulin Degludec / Liraglutide Injectable Product","genericName":"Insulin Degludec / Liraglutide Injectable Product","companyName":"University of Palermo","companyId":"university-of-palermo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination product uses insulin degludec to provide long-acting basal insulin coverage and liraglutide to stimulate GLP-1 receptors, enhancing insulin secretion and reducing appetite for improved glycemic control. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}